Align Technology Announces First Quarter 2023 Financial Results

Delivers revenue and EPS ahead of expectations, with total Invisalign® patients treated surpassing 15 million globally

Completes May 13, 2021 $1 Billion Stock Repurchase Program

Q1’23 total revenues of $943.1 million, increased 4.6% sequentially, and diluted net income per share of $1.14, non-GAAP diluted net income per share of $1.82

Q1’23 revenues were favorably impacted by foreign exchange of approximately $25.8 million sequentially and unfavorably impacted by approximately $34.9 million year over year(1)

Q1’23 operating income of $133.5 million and operating margin of 14.2%, non-GAAP operating margin of 18.5%

Q1’23 GAAP operating margin was favorably impacted by foreign exchange of approximately 1.5 points sequentially and unfavorably impacted by approximately 2.0 points year over year.(1)

Q1’23 Clear Aligner revenues of $789.8 million, increased 7.9% sequentially, and Clear Aligner volume of 575.4 thousand cases, decreased 1.4% sequentially

Q1’23 Imaging Systems and CAD/CAM Services revenues of $153.3 million, decreased 9.7% sequentially

Purchased approximately 942 thousand shares of Align’s common stock at an average price of $307.74 per share for a total purchase price of $290.0 million, completing Align’s May 13, 2021 $1 Billion Stock Repurchase Program

TEMPE, Ariz.–(BUSINESS WIRE)–Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today reported financial results for the first quarter (“Q1’23”). Q1’23 total revenues were $943.1 million, up 4.6% sequentially and down 3.1% year-over-year. Q1’23 Clear Aligner revenues were $789.8 million, up 7.9% sequentially and down 2.5% year-over-year. Q1’23 Clear Aligner volume was down 1.4% sequentially and down 3.9% year-over-year. Q1’23 Imaging Systems and CAD/CAM Services revenues were $153.3 million, down 9.7% sequentially and down 6.2% year-over-year. Q1’23 Clear Aligner revenues were favorably impacted by foreign exchange of approximately $21.8 million or 2.8% sequentially and unfavorably impacted by approximately $29.1 million or 3.6% year over year.(1) Q1’23 Imaging Systems and CAD/CAM Services revenues were favorably impacted by foreign exchange of approximately $4.0 million or 2.7% sequentially and unfavorably impacted by approximately $5.8 million or 3.6% year over year.(1) Q1’23 operating income was $133.5 million resulting in an operating margin of 14.2%. Q1’23 operating margin was favorably impacted by foreign exchange of approximately 1.5 points sequentially and unfavorably impacted by approximately 2.0 points year over year.(1) Q1’23 net income was $87.8 million, or $1.14 per diluted share. On a non-GAAP basis, Q1’23 net income was $140.6 million, or $1.82 per diluted share.

(1) Non-GAAP measure

Commenting on Align’s Q1’23 results, Align Technology President and CEO Joe Hogan said, “Overall, I’m pleased to report better than expected first quarter revenues and earnings. Our first quarter revenues of $943.1 million, a sequential increase, reflect stability across all regions for our Clear Aligner business and favorable average selling price (“ASP”) for the Clear Aligner and Systems and Services segments. Q1 sequential growth reflects an increase in Non-Case revenues which also increased year over year, driven by continued growth from our Invisalign® Doctor Subscription Program (“DSP”) and Vivera™ retainers. In the teen segment, which represents the largest portion of the 21 million annual orthodontic case starts, 182 thousand teens and kids started treatment with Invisalign clear aligners during the first quarter, increasing both sequentially and year over year, which is encouraging as we head into the important summer season for teens and kids. Overall, we remain confident in our large underpenetrated market opportunity globally and our ability to deliver digital products and technology that are helping doctors transform smiles and change lives for millions of people.”

Financial Summary – First Quarter Fiscal 2023

 

Q1’23

 

Q4’22

 

Q1’22

 

Q/Q Change

 

Y/Y Change

Clear Aligner Shipments

 

575,395

 

 

583,720

 

 

598,835

 

(1.4

)%

 

 

(3.9

)%

GAAP

 

 

 

 

 

 

 

 

 

Net Revenues

$

943.1M

 

$

901.5M

 

$

973.2M

 

+4.6

%

 

 

(3.1

)%

Clear Aligner

$

789.8M

 

$

731.7M

 

$

809.7M

 

+7.9

%

 

 

(2.5

)%

Imaging Systems and CAD/CAM Services

$

153.3M

 

$

169.9M

 

$

163.5M

 

(9.7

)%

 

 

(6.2

)%

Net Income

$

87.8M

 

$

41.8M

 

$

134.3M

 

+110.2

%

 

 

(34.6

)%

Diluted EPS

$

1.14

 

$

0.54

 

$

1.70

 

+$0.60

 

($

0.56

)

Non-GAAP

 

 

 

 

 

 

 

 

 

Net Income

$

140.6M

 

$

134.2M

 

$

178.0M

 

+4.8

%

 

 

(21.0

)%

Diluted EPS

$

1.82

 

$

1.73

 

$

2.25

 

+$0.09

 

($

0.43

)

Changes and percentages are based on actual values. Certain tables may not sum or recalculate due to rounding.

As of March 31, 2023, we had over $921.4 million in cash, cash equivalents and short-term and long-term marketable securities compared to over $1.0 billion as of December 31, 2022. As of March 31, 2023, we had $300.0 million available under a revolving line of credit which was amended during Q4 2022 to extend the term through 2027. During Q1’23, we purchased approximately 942 thousand shares of our common stock at an average price of $307.74 per share, completing a $200.0 million Accelerated Share Repurchase (“ASR”) from Q4’22, a $250.0 million ASR from Q1 2023, and our May 13, 2021 $1.0 Billion Stock Repurchase Program. During Q1’23, we announced that our Board of Directors authorized a new $1.0 Billion Stock Repurchase Program to succeed the 2021 $1 billion program. Currently $1.0 billion remains available for repurchases under the 2023 $1.0 Billion Stock Repurchase Program.

Q1’23 Announcement Highlights

On February 6, 2023, we announced that we entered into a new ASR agreement with Citibank, N.A., to repurchase $250.0 million of our common stock under our May 13, 2021, $1.0 Billion Stock Repurchase Program. In addition to the ASR, Align announced that Joe Hogan, president and CEO and John Morici, CFO and executive vice president, global finance intended to personally purchase $1.0 million and $0.2 million, respectively, of Align’s common stock.

On February 8, 2023, we announced the appointment of Karim Boussebaa as executive vice president and managing director of iTero scanner and services business. Mr. Boussebaa is an experienced healthcare executive with more than 28 years of industry leadership and a proven track record of innovation and organizational development, and extensive regulatory experience.

Fiscal 2023 Business Outlook

For 2023, Align provides the following business outlook:

For Q2’23, we anticipate Clear Aligner volume and ASP to be up sequentially. We also anticipate Systems and Services revenue to be up sequentially. We anticipate Q2’23 revenues to be in the range of $980 million to $1,000 million. We expect our Q2’23 GAAP and Non-GAAP gross margin to be flat to slightly up from Q1’23, and our Q2’23 GAAP and Non-GAAP operating margin to be up by approximately 1 point sequentially, as we continue to strategically prioritize our investments in go-to-market activities and R&D to drive growth.

For full year 2023, assuming no circumstances beyond our control occur, we are reiterating our 2023 GAAP operating margin to be slightly above 16% and our 2023 Non-GAAP operating margin to be slightly above 20%.

For 2023, we expect investments in capital expenditures to exceed $200 million. Capital expenditures are expected to primarily relate to building construction and improvements as well as additional manufacturing capacity in support of our continued international expansion.

Align Web Cast and Conference Call

We will host a conference call today, April 26, 2023, at 4:30 p.m. ET, 1:30 p.m. PT, to review our first quarter 2023 results, discuss future operating trends, and our business outlook. The conference call will also be webcast live via the Internet. To access the webcast, go to the “Events & Presentations” section under Company Information on Align’s Investor Relations website at http://investor.aligntech.com. To access the conference call, please dial 833-470-1428 with access code 282632. An archived audio webcast will be available beginning approximately one hour after the call’s conclusion and will remain available for approximately one month. Additionally, a telephonic replay of the call can be accessed by dialing 929-458-6194 with access code 635629. For international callers, please dial 44-204-525-0658 and use the same access code referenced above. The telephonic replay will be available through 5:30 p.m. ET on May 10, 2023.

About Non-GAAP Financial Measures

To supplement our condensed consolidated financial statements, which are prepared and presented in accordance with generally accepted accounting principles in the United States (“GAAP”), we may provide investors with certain non-GAAP financial measures which may include constant currency net revenues, constant currency gross profit, constant currency gross margin, constant currency income from operations, constant currency operating margin, gross profit, gross margin, operating expenses, income from operations, operating margin, interest income and other income (expense), net, net income before provision for income taxes, provision for income taxes, effective tax rate, net income and/or diluted net income per share, which excludes certain items that may not be indicative of our fundamental operating performance including, foreign currency exchange rate impacts and discrete cash and non-cash charges or gains that are included in the most directly comparable GAAP measure. In Q4’22, we changed to a long-term non-GAAP effective tax rate in our computation of the non-GAAP income tax provision to provide better consistency across reporting periods. Our previous methodology for calculating our non-GAAP effective tax rate included certain non-recurring and period-specific items, that produced fluctuating effective tax rates that management does not believe are reflective of the Company’s long-term effective tax rate. This new methodology became effective January 1, 2022 and we recast prior periods in 2022. Unless otherwise indicated, when we refer to non-GAAP financial measures they will exclude the effects of stock-based compensation, amortization of certain acquired intangibles, restructuring and other charges, acquisition-related costs, and arbitration award gain, and associated tax impacts.

Our management believes that the use of certain non-GAAP financial measures provides meaningful supplemental information regarding our recurring core operating performance. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the performance of our business.

There are limitations to using non-GAAP financial measures as they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact upon our reported financial results. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which charges are excluded from the non-GAAP financial measures. We compensate for these limitations by analyzing current and future results on a GAAP as well as a non-GAAP basis and by providing GAAP measures in our public disclosures. The presentation of non-GAAP financial information is meant to be considered in addition to, not as a substitute for or in isolation from, the directly comparable financial measures prepared in accordance with GAAP. We urge investors to review the reconciliation of our GAAP financial measures to the comparable non-GAAP financial measures included herein and not to rely on any single financial measure to evaluate our business. For more information on these non-GAAP financial measures, please see the tables captioned “Unaudited GAAP to Non-GAAP Reconciliation.”

About Align Technology, Inc.

Align Technology designs and manufactures the Invisalign® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for approximately 243 thousand doctor customers and are key to accessing Align’s 500 million consumer market opportunity worldwide. Over the past 25 years, Align has helped doctors treat over 15.1 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align Digital Platform™, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.

For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.

Invisalign, iTero, exocad, Align, and Align Digital Platform are trademarks of Align Technology, Inc.

Forward-Looking Statements

This news release, including the tables below, contains forward-looking statements, including statements of beliefs and expectations regarding market opportunities, our ability to deliver products and technologies, anticipated clear aligner volumes and ASP, anticipated Systems and Services revenue, our expectations for Q2’23 revenues, GAAP and Non-GAAP gross margin and GAAP and Non-GAAP operating margin, and 2023 GAAP and Non-GAAP operating margin, as well as capital expenditures. Forward-looking statements contained in this news release relating to expectations about future events or results are based upon information available to Align as of the date hereof. Readers are cautioned that these forward-looking statements reflect our best judgments based on currently known facts and circumstances and are subject to risks, uncertainties, and assumptions that are difficult to predict. As a result, actual results may differ materially and adversely from those expressed in any forward-looking statement.

Factors that might cause such a difference include, but are not limited to:

macroeconomic conditions, including inflation, fluctuations in currency exchange rates, rising interest rates, market volatility, weakness in general economic conditions and recessions and the impact of efforts by central banks and federal, state and local governments to combat inflation and recession;

customer and consumer purchasing behavior and changes in consumer spending habits as a result of, among other things, prevailing macro-economic conditions, levels of employment, salaries and wages, debt obligations, discretionary income, inflationary pressure, declining consumer confidence, and the military conflict in Ukraine;

the economic and geopolitical ramifications of the military conflict in Ukraine, including sanctions, retaliatory sanctions, nationalism, supply chain disruptions and other consequences, any of which may or will continue to adversely impact our operations and research and development activities inside and outside of Russia;

variations in our product mix and selling prices regionally and globally;

the timing and availability and cost of raw materials, components, products and other shipping and supply chain constraints;

unexpected or rapid changes in the growth or decline of our domestic and/or international markets;

competition from existing and new competitors;

rapidly evolving and groundbreaking advances that fundamentally alter the dental industry or the way new and existing customers market and provide products and services to consumers;

the ability to protect our intellectual property rights;

continued compliance with regulatory requirements;

declines in, or the slowing of the growth of, sales of our clear aligners and intraoral scanners domestically and/or internationally and the impact either would have on the adoption of Invisalign products;

the willingness and ability of our customers to maintain and/or increase product utilization in sufficient numbers;

the possibility that the development and release of new products or enhancements to existing products do not proceed in accordance with the anticipated timeline or may themselves contain bugs, errors or defects in software or hardware requiring remediation and that the market for the sale of these new or enhanced products may not develop as expected;

a tougher consumer demand environment in China generally, especially for manufacturers and service providers whose headquarters or primary operations are not based in China;

the risks relating to our ability to sustain or increase profitability or revenue growth in future periods (or minimize declines) while controlling expenses;

expansion of our business and products;

the impact of excess or constrained capacity at our manufacturing and treat operations facilities and pressure on our internal systems and personnel;

the compromise of our systems or networks, including any customer and/or patient data contained therein, for any reason;

the timing of case submissions from our doctor customers within a quarter as well as an increased manufacturing costs per case;

foreign operational, political, military and other risks relating to our operations; and

the loss of key personnel, labor shortages or work stoppages for us or our suppliers.

The foregoing and other risks are detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including, but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission (“SEC”) on February 27, 2023. Align undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

ALIGN TECHNOLOGY, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

 

 

Three Months Ended

March 31,

 

 

2023

 

2022

Net revenues

 

$

943,147

 

 

$

973,219

 

Cost of net revenues

 

 

282,493

 

 

 

263,873

 

Gross profit

 

 

660,654

 

 

 

709,346

 

Operating expenses:

 

 

 

 

Selling, general and administrative

 

 

439,691

 

 

 

439,457

 

Research and development

 

 

87,447

 

 

 

71,807

 

Total operating expenses

 

 

527,138

 

 

 

511,264

 

Income from operations

 

 

133,516

 

 

 

198,082

 

Interest income and other income (expense), net:

 

 

 

 

Interest income

 

 

2,337

 

 

 

677

 

Other income (expense), net

 

 

(1,229

)

 

 

(11,273

)

Total interest income and other income (expense), net

 

 

1,108

 

 

 

(10,596

)

Net income before provision for income taxes

 

 

134,624

 

 

 

187,486

 

Provision for income taxes

 

 

46,826

 

 

 

53,188

 

Net income

 

$

87,798

 

 

$

134,298

 

 

 

 

 

 

Net income per share:

 

 

 

 

Basic

 

$

1.14

 

 

$

1.71

 

Diluted

 

$

1.14

 

 

$

1.70

 

Shares used in computing net income per share:

 

 

 

 

Basic

 

 

76,921

 

 

 

78,742

 

Diluted

 

 

77,111

 

 

 

79,193

 

ALIGN TECHNOLOGY, INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

 

 

March 31,
2023

 

December 31,
2022

ASSETS

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

 

$

832,383

 

$

942,050

Marketable securities, short-term

 

 

51,644

 

 

57,534

Accounts receivable, net

 

 

884,430

 

 

859,685

Inventories

 

 

311,885

 

 

338,752

Prepaid expenses and other current assets

 

 

251,540

 

 

226,370

Total current assets

 

 

2,331,882

 

 

2,424,391

 

 

 

 

 

Marketable securities, long-term

 

 

37,379

 

 

41,978

Property, plant and equipment, net

 

 

1,262,815

 

 

1,231,855

Operating lease right-of-use assets, net

 

 

117,889

 

 

118,880

Goodwill

 

 

414,222

 

 

407,551

Intangible assets, net

 

 

93,320

 

 

95,720

Deferred tax assets

 

 

1,589,640

 

 

1,571,746

Other assets

 

 

54,301

 

 

55,826

 

 

 

 

 

Total assets

 

$

5,901,448

 

$

5,947,947

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

Accounts payable

 

$

130,561

 

$

127,870

Accrued liabilities

 

 

497,248

 

 

454,374

Deferred revenues

 

 

1,376,789

 

 

1,343,643

Total current liabilities

 

 

2,004,598

 

 

1,925,887

 

 

 

 

 

Income tax payable

 

 

126,541

 

 

124,393

Operating lease liabilities

 

 

99,002

 

 

100,334

Other long-term liabilities

 

 

191,258

 

 

195,975

Total liabilities

 

 

2,421,399

 

 

2,346,589

 

 

 

 

 

Total stockholders’ equity

 

 

3,480,049

 

 

3,601,358

 

 

 

 

 

Total liabilities and stockholders’ equity

 

$

5,901,448

 

$

5,947,947

ALIGN TECHNOLOGY, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

 

 

Three Months Ended
March 31,

 

 

2023

 

2022

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

Net cash provided by operating activities

 

$

199,895

 

 

$

30,498

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES

 

 

 

 

Net cash used in investing activities

 

 

(52,829

)

 

 

(90,198

)

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

Net cash used in financing activities

 

 

(258,961

)

 

 

(111,742

)

 

 

 

 

 

Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash

 

 

2,221

 

 

 

(1,826

)

Net (decrease) increase in cash, cash equivalents, and restricted cash

 

 

(109,674

)

 

 

(173,268

)

Cash, cash equivalents, and restricted cash at beginning of the period

 

 

942,355

 

 

 

1,100,139

 

Cash, cash equivalents, and restricted cash at end of the period

 

$

832,681

 

 

$

926,871

 

ALIGN TECHNOLOGY, INC.

INVISALIGN BUSINESS METRICS

 

 

Q1

 

Q2

 

Q3

 

Q4

 

Q1

 

 

2022

 

2022

 

2022

 

2022

 

2023

Number of Invisalign Trained Doctors Cases Were Shipped To

 

 

82,440

 

 

82,275

 

 

84,410

 

 

82,865

 

 

82,685

 

 

 

 

 

 

 

 

 

 

 

Invisalign Trained Doctor Utilization Rates*:

 

 

 

 

 

 

 

 

 

 

North America

 

 

9.2

 

 

9.3

 

 

8.9

 

 

8.8

 

 

9.0

North American Orthodontists

 

 

26.8

 

 

26.8

 

 

25.9

 

 

24.8

 

 

26.2

North American GP Dentists

 

 

5.0

 

 

5.1

 

 

4.8

 

 

5.0

 

 

4.9

International

 

 

6.4

 

 

6.4

 

 

6.0

 

 

6.5

 

 

6.2

Total Utilization Rates**

 

 

7.3

 

 

7.3

 

 

6.8

 

 

7.0

 

 

7.0

 

 

 

 

 

 

 

 

 

 

 

Clear Aligner Revenue Per Case Shipment***:

 

$

1,350

 

$

1,335

 

$

1,270

 

$

1,255

 

$

1,375

* # of cases shipped / # of doctors to whom cases were shipped

** LATAM utilization rate is not separately disclosed but included in the total utilization rates

*** Clear Aligner revenues / Case shipments

ALIGN TECHNOLOGY, INC.

STOCK-BASED COMPENSATION

(in thousands)

 

 

Q1

 

Q2

 

Q3

 

Q4

 

Fiscal

 

Q1

 

 

2022

 

2022

 

2022

 

2022

 

2022

 

2023

Stock-based Compensation (SBC):

 

 

 

 

 

 

 

 

 

 

 

 

SBC included in Gross Profit

 

$

1,514

 

$

1,614

 

$

1,651

 

$

1,659

 

$

6,438

 

$

1,807

SBC included in Operating Expenses

 

 

30,107

 

 

32,526

 

 

31,267

 

 

33,029

 

 

126,929

 

 

35,928

Total SBC

 

$

31,621

 

$

34,140

 

$

32,918

 

$

34,688

 

$

133,367

 

$

37,735

 

 

 

 

 

 

 

 

 

 

 

 

 

ALIGN TECHNOLOGY, INC.

UNAUDITED GAAP TO NON-GAAP RECONCILIATION

CONSTANT CURRENCY NET REVENUES

(in thousands, except percentages)

Sequential constant currency analysis:

 

 

Three Months Ended

 

 

 

 

March 31,

2023

 

December 31,
2022

 

Impact % of

Revenue

GAAP net revenues

 

$

943,147

 

 

$

901,515

 

 

Constant currency impact (1)

 

 

(25,798

)

 

 

 

(2.8

) %

Constant currency net revenues (1)

 

$

917,349

 

 

 

 

 

 

 

 

 

 

 

 

GAAP Clear Aligner net revenues

 

$

789,804

 

 

$

731,654

 

 

Clear Aligner constant currency impact (1)

 

 

(21,780

)

 

 

 

(2.8

) %

Clear Aligner constant currency net revenues (1)

 

$

768,024

 

 

 

 

 

 

 

 

 

 

 

 

GAAP Imaging Systems and CAD/CAM Services net revenues

 

$

153,343

 

 

$

169,861

 

 

Imaging Systems and CAD/CAM Services constant currency impact (1)

 

 

(4,018

)

 

 

 

(2.7

) %

Imaging Systems and CAD/CAM Services constant currency net revenues (1)

 

$

149,325

 

 

 

 

 

Contacts

Align Technology
Madelyn Valente

(909) 833-5839

[email protected]

Zeno Group
Sarah Johnson

(828) 551-4201

[email protected]

Read full story here

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Generated by Feedzy
TradeWinds at MEDICA Germany

Dusseldorf, Germany 13-16 November 2023

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.